Beyond low-density lipoprotein cholesterol: A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess

Archives of Internal Medicine

Volumn 156, Issue 12, 1996, Pages 1278-1284

  Rosenson, Robert S ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; BEZAFIBRATE; COLESTIPOL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEOMYCIN; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY RISK; DIET THERAPY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN(A);

EID: 0029922701     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.12.1278     Document Type: Review

References (89)

1. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1986; 148:36-69.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
3. Multiple Risk Factor Intervention Trial Research Group (MRFIT). Relationship between baseline risk factors and coronary heart disease and total mortality in the multiple risk factor. Prev Med. 1986;15:254-273.
4. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
5. Rosenson RS, Frauenheim WA, Tangney CC. Dyslipidemias and the secondary prevention of coronary heart disease. Dis Mon. 1994;40:369-464.
6. Rosenson RS. Reversing coronary artery disease: diet-based strategies. Phys Sportsmed. 1994; 22(11):59-64.
7. Study Group of the European Atherosclerosis Society. The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J. 1988;9:571-600.
8. The Canadian Consensus Conference on Cholesterol. Final report. Can Med Assoc J. 1988; 26:369-388.
9. The Lipid Research Clinics Program Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984; 251:351-364.
10. The Lipid Research Clinics Program Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251:365-374.
11. Frick MG, Elo O, Haapa K, et al. Helsinki Heart Study, primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
13. Coronary Drug Project Research Group. The Coronary Drug Project: clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
14. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
15. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME, for the PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
16. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
18. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
19. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? the Lifestyle Heart Trial. Lancet. 1990; 336:129-133.
20. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
21. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-1298.
22. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia, N Engl J Med. 1990;323: 946-955.
23. Thompson GR, Maher VMG, Matthews S, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811-816.
24. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
25. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
26. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119: 969-976.
27. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994; 89:959-968.
28. MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
29. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
30. Grossman M, Raper SE, Kozarsky K, et al. Successful ex-vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet. 1994;6:335-341.
31. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;4:32-38.
32. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA. 1993;269:3002-3008.
33. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269: 3009-3014.
34. Williams R, Hunt SC, Schumacher C, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171-176.
35. Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoproteins A-1 and B, and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.
36. Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged ≤50 years) and women (≤60 years) with coronary artery disease. Am J Cardiol. 1993;71:631-639.
37. Genest JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
38. Genest J Jr, Bard JM, Fruchart JC, Ordovas JM, Schaefer EJ. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1993;13:1728-1737.
39. Rosenson RS. Low levels of high-density lipoprotein cholesterol (hypoalphalipoproteinemia): an approach to management. Arch Intern Med. 1993;153:1528-1538.
40. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J. 1983;106:1191-1200.
41. The Bezafibrate Infarction Prevention Study Group. Lipids and lipoproteins in symptomatic coronary heart disease: distribution, intercorrelation and significance for risk classification in 6700 men and 1500 women. Circulation. 1992;86: 839-848.
42. Glueck CJ, Daniels SR, Bates S, Benton C, Tracy T, Third JL. Pediatric victims of unexplained stroke and their families: familial lipid and lipoprotein abnormalities. Pediatrics. 1982;69:308-316.
43. Vergani C, Bettale G. Familial hypoalphalipoproteinemia. Clin Chim Acta. 1981;114:45-52.
44. Rader DJ, Ikewaki K, Duverger N, et al. Very low high-density lipoproteins without coronary atherosclerosis. Lancet. 1993;342:1455-1458.
45. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest. 1990;86:379-384.
46. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
47. Bekaert ED, Alaupovic P, Knight-Gibson CS, Franceschini G, Sirtori CR. Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles. J Lipid Res. 1994;34:111-123.
48. Tertov W, Sobenin IA, Gabbasov ZA, Popov EG, Orekhov AN. Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem Biophys Res Commun. 1989;163:489-494.
49. Oram JF, Johnson CJ, Brown TA. Interaction of high density lipoprotein with its receptor on cultured fibroblasts and macrophages: evidence for reversible binding at the cell surface without internalization. J Biol Chem. 1987;262:2405-2410.
50. Tauber J, Cheng J, Gospodarowicz D. Effect of high and low density lipoproteins on proliferation of cultured bovine vascular endothelial cells. J Clin Invest. 1980;66:696-708.
51. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol. 1991;68:1425-1430.
52. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res. 1985;39:1-8.
53. Epand RM, Stafford A, Leon B, et al. HDL and apolipoprotein A-1 protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb Vasc Biol. 1994;14:1775-1783.
54. Knorr M, Locher R, Vogl E, et al. Rapid activation of human platelets by low concentrations of low-density lipoprotein via phosphatidylinositol cycle. Eur J Biochem. 1988;1972:753-759.
55. Stamos TD, Rosenson RS. Low HDL is associated with increases in blood viscosity in subjects with normal triglycerides. Biotheology. 1995; 32:316. Abstract
56. 2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation. 1990;81:1784-1791.
57. Gordon DJ, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and disease: four prospective American studies. Circulation. 1989;79:8-15.
58. Barth JD, Jansen H, Kromhourt D, Reiber JH, Birkenhager JC, Arntzenius AC. Progression and regression of human coronary atherosclerosis. The role of lipoproteins, lipases and thyroid hormones in coronary lesion growth. Atherosclerosis. 1987;68:51-58.
59. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
60. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85: 37-45.
61. LaRosa JC, Cleeman JI. Cholesterol lowering as a treatment for established coronary heart disease. Circulation. 1992;85:1229-1235.
62. Gotto AM. Hypertriglyceridemia: risks and perspectives. Am J Cardiol. 1992;70:19H-25H
63. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994; 154:73-82.
64. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol. 1992;69:1083-1085
65. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
66. Alexander LC, Lawn RM. Vascular interactions of lipoprotein(a). Curr Opin Lipidol. 1994;5:269-273.
67. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330: 132-137.
68. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA. 1989;86:3847-3851.
69. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest. 1991;87:767-771.
70. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocytemacrophages. J Biol Chem. 1992;267:4143-4151.
71. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1658.
72. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544.
73. Pedro-Botet J, Senti M, Nogues X, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke: role of lipoprotein(a), triglyceriderich lipoproteins, and apolipoprotein E polymorphism. Stroke. 1992;23:1556-1562.
74. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke. 1993;24:965-969.
75. Molgaard J, Klausen IC, Lassvik C, Faergeman P, Gerdes LU, Olsson AG. Significant association between low molecular weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb Vasc Biol. 1992;12:895-901.
76. Cambillau M, Simon A, Amar J, et al, and the PVCMETRA Group. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. Arterioscler Thromb. 1992;12:1346-1352.
77. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145-150.
78. Rosenson RS. Myocardial injury, the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22:933-940.
79. Rosengren A, Wilhelmsen L, Erikssen E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective study in a general population sample of middle aged men. BMJ. 1990;301:1248-1251.
80. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
81. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
82. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischemic heart disease: implications for screening. Lancet. 1994;343:75-79.
83. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271: 999-1003.
84. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24:444-453.
85. Cantin B, Moorjani S, Dagenais GR, Lupien P-J. Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (The Quebec Cardiovascular Study). Am J Coll Cardiol. 1995;75:1224-1228.
86. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. Circulation. 1994; 90:1688-1695.
87. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis. 1985;5:265-272.
88. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
89. Gurakar A, Hoeg JM, Kostner G, et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301.